Summary
Global Markets Direct’s, ‘Schistosomiasis - Pipeline Review, H1 2016’, provides an overview of the Schistosomiasis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Schistosomiasis
- The report reviews pipeline therapeutics for Schistosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Schistosomiasis therapeutics and enlists all their major and minor projects
- The report assesses Schistosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Schistosomiasis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Schistosomiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
BioDiem Ltd
Concert Pharmaceuticals, Inc.
Kancera AB
LondonPharma Ltd
Merck KGaA
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Schistosomiasis Overview 6
Therapeutics Development 7
Pipeline Products for Schistosomiasis - Overview 7
Pipeline Products for Schistosomiasis - Comparative Analysis 8
Schistosomiasis - Therapeutics under Development by Companies 9
Schistosomiasis - Therapeutics under Investigation by Universities/Institutes 10
Schistosomiasis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Schistosomiasis - Products under Development by Companies 13
Schistosomiasis - Products under Investigation by Universities/Institutes 14
Schistosomiasis - Companies Involved in Therapeutics Development 15
BioDiem Ltd 15
Concert Pharmaceuticals, Inc. 16
Kancera AB 17
LondonPharma Ltd 18
Merck KGaA 19
Schistosomiasis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
BDM-I - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
D-Praziquantel - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
intestinal schistosomiasis vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
intestinal schistosomiasis vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
L-Praziquantel - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule for Schistosomiasis - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule for Schistosomiasis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Schistosomiasis - Recent Pipeline Updates 36
Schistosomiasis - Dormant Projects 38
Schistosomiasis - Product Development Milestones 39
Featured News & Press Releases 39
Aug 23, 2013: BioDiem US patent for skin and wound infections 39
Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites 39
Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I 39
Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I 40
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43
List of Tables
Number of Products under Development for Schistosomiasis, H1 2016 7
Number of Products under Development for Schistosomiasis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Schistosomiasis - Pipeline by BioDiem Ltd, H1 2016 15
Schistosomiasis - Pipeline by Concert Pharmaceuticals, Inc., H1 2016 16
Schistosomiasis - Pipeline by Kancera AB, H1 2016 17
Schistosomiasis - Pipeline by LondonPharma Ltd, H1 2016 18
Schistosomiasis - Pipeline by Merck KGaA, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Schistosomiasis Therapeutics - Recent Pipeline Updates, H1 2016 36
Schistosomiasis - Dormant Projects, H1 2016 38
List of Figures
Number of Products under Development for Schistosomiasis, H1 2016 7
Number of Products under Development for Schistosomiasis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Routes of Administration, H1 2016 23
Number of Products by Stage and Routes of Administration, H1 2016 23
Number of Products by Molecule Types, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 25
